- Home
- SBR vs GHRS Comparison
SBR vs GHRS Comparison
Compare SBR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- GHRS
- Stock Information
- Founded
- SBR 1982
- GHRS 2018
- Country
- SBR United States
- GHRS Ireland
- Employees
- SBR N/A
- GHRS N/A
- Industry
- SBR Oil & Gas Production
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SBR Energy
- GHRS Health Care
- Exchange
- SBR Nasdaq
- GHRS Nasdaq
- Market Cap
- SBR 972.2M
- GHRS 960.2M
- IPO Year
- SBR N/A
- GHRS 2021
- Fundamental
- Price
- SBR $66.25
- GHRS $17.57
- Analyst Decision
- SBR
- GHRS Strong Buy
- Analyst Count
- SBR 0
- GHRS 8
- Target Price
- SBR N/A
- GHRS $30.63
- AVG Volume (30 Days)
- SBR 27.0K
- GHRS 185.2K
- Earning Date
- SBR 01-01-0001
- GHRS 09-02-2025
- Dividend Yield
- SBR 7.60%
- GHRS N/A
- EPS Growth
- SBR N/A
- GHRS N/A
- EPS
- SBR 5.34
- GHRS N/A
- Revenue
- SBR $81,761,891.00
- GHRS N/A
- Revenue This Year
- SBR N/A
- GHRS N/A
- Revenue Next Year
- SBR N/A
- GHRS N/A
- P/E Ratio
- SBR $12.32
- GHRS N/A
- Revenue Growth
- SBR N/A
- GHRS N/A
- 52 Week Low
- SBR $58.25
- GHRS $6.00
- 52 Week High
- SBR $70.20
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- SBR 47.70
- GHRS 71.70
- Support Level
- SBR $65.35
- GHRS $15.25
- Resistance Level
- SBR $67.30
- GHRS $16.90
- Average True Range (ATR)
- SBR 0.92
- GHRS 1.22
- MACD
- SBR -0.08
- GHRS 0.28
- Stochastic Oscillator
- SBR 27.74
- GHRS 83.45
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.